of COVID-19 Vaccines to Patients Receiving Abasaglar
acute respiratory syndrome coronavirus 2 is an emerging virus that
has caused the COVID-19 pandemic. Recently, vaccines have been
developed against SARS-CoV-2 and some of them are already
Vaccination With Abasaglar
use of a SARS-CoV-2 vaccine in patients treated with Abasaglar has
not been studied by Lilly.
regarding the use of any vaccination, including SARS-CoV-2 vaccines,
in patients treated with Abasaglar should be made at the discretion
of the prescribing physician using their best clinical judgment, and
must be made by the clinician after careful consideration of risk
factors of the patient and the risks and benefits of vaccination.
impact of vaccination on blood glucose concentration
International Diabetes Federation IDF states that after any
vaccination the blood glucose levels might rise for a few days.5
resources on COVID-19 Vaccines and Diabetes
information on COVID-19 vaccines and diabetes, please refer to
current information on COVID-19 and COVID-19 vaccines in general,
please refer to
Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2
vaccine candidates. Signal Transduct Target Ther.
Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group.
An mRNA vaccine against SARS-CoV-2 — preliminary report. N
Engl J Med. 2020;383(20):1920-1931.
COVID-19 vaccines. Centers for Disease Control and Prevention.
Updated December 31, 2020. Accessed January 4, 2021.
Draft landscape of COVID-19 candidate vaccines. World Health
Organization (WHO). November 12, 2020. Accessed December 4, 2020.
International Diabetes Federation Europe. Diabetes & Coronavirus
Accessed April 29, 2021
Coronavirus disease (COVID-19) outbreak. European web page of the
World Health Organization. Accessed March 20, 2020.
International Diabetes Federation Europe. COVID-19 outbreak:
guidance for people with diabetes.
Accessed March 18, 2020
COVID-19. European Centre for Disease Prevention and Control.
Accessed March 20, 2020.
= Abasaglar® (insulin glargine) 100 units/mL
= coronavirus disease 2019
= Eli Lilly and Company
= severe acute respiratory syndrome coronavirus 2